9月28日，西班牙最高科研理事会（CSIC）正式宣布，其所属的西班牙国家生物技术中心已成功研制出“国产”预防性艾滋病疫苗MVA-B。科学家们对24名接受该疫苗注射的健康志愿者进行了临床检测，结果表明，22人的体内对HIV病毒产生了抗体，其中20人的免疫能力持续达到一年以上。
CSIC表示，科学家们完成的上述临床Ⅰ期，已证实MVA-B疫苗可积极防御HIV病毒入侵，安全有效性得到了验证。下一步将针对已感染HIV病毒患者，进行Ⅱ期临床试验研究，观察其免疫反应，甄别和分析MVA-B疫苗的治疗作用。如果前景看好，预计五年内将启动实施Ⅲ期临床，进行大规模接种观察，以期充分验证MVA-B疫苗保护免受HIV病毒感染或避免发病的效力，实现获准生产和应用的目标。
MVA-B疫苗是西班牙开展艾滋病疫苗研制十余年的首发科研成果，相关论文已公开发表在国际权威期刊《Journal of Virology》和《Vaccine》上。
艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复
 |
| 图示∶2011年5月正式出版的《中国特色医疗金鉴》登载的刘君主任及其机构事迹 |
| |
|
|
Spain achieved initial results of AIDS vaccine development
Science and Technology portal www.most.gov.cn 2011 年 10 月 26 MVP: Science and Technology
September 28, the highest Spanish Research Council (CSIC) formally announced that it belongs to the Spanish National Biotechnology Center has successfully developed a "domestic" preventive AIDS vaccine MVA-B. 24 scientists to accept the vaccination of healthy volunteers in clinical testing, results showed that 22 of the body produced antibodies against HIV, 20 of whom sustained immunity to more than one year.
CSIC said scientists completed the clinical stage Ⅰ, has confirmed that MVA-B HIV vaccine viruses active defense, safety and efficacy has been verified. The next step will be for patients already infected with HIV, the phase Ⅱ clinical trial to observe the immune response, screening and analysis of MVA-B vaccine treatment. If prospects are expected to start within five years to implement Phase Ⅲ clinical observation of large-scale vaccination, in order to fully verify the MVA-B vaccine protects against HIV infection or prevent onset of effect, allowed the production and application to achieve the goal.
MVA-B vaccine in Spain more than ten years of AIDS vaccine development, the first scientific research, the relevant papers have been published in the international authoritative journal "Journal of Virology" and "Vaccine" on.
